Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis

por Hadi, I., Schummer, A., Dreyling, M., Eze, C., Bodensohn, R., Roengvoraphoj, O., Belka, C., Li, M.
Publicado 2021

P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTOR...

por Yazji, S., Hamburger, S., Wang, Y., Yavrom, S., Pietrofeso, A., Bliss, R., Breitmeyer, J. B., Dreyling, M., Wang, M.
Publicado 2022

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUS...

por Belada, D., Kopeckova, K., Bergua Burgues, J. M., Stevens, D., Nowakowski, G. S., Waldron-Lynch, M., Hadar, N., Weirather, J., Lässig, C., Blair, D., Dreyling, M.
Publicado 2022

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

por Rule, S, Jurczak, W, Jerkeman, M, Rusconi, C, Trneny, M, Offner, F, Caballero, D, Joao, C, Witzens-Harig, M, Hess, G, Bence-Bruckler, I, Cho, S-G, Thieblemont, C, Zhou, W, Henninger, T, Goldberg, J, Vermeulen, J, Dreyling, M
Publicado 2018

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (...

por Eyre, T. A., Shah, N. N., Le Gouill, S., Dreyling, M., Vandenberghe, E., Jurczak, W., Wang, Y., Cheah, C. Y., Gandhi, M., Chay, C., Sharman, J. P., Andorsky, D. J., Yin, M., Balbas, M., Kherani, J., Wang, M. L.
Publicado 2022

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

por Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. H., Zinzani, P. L.
Publicado 2017

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

por Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F.
Publicado 2022

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

por Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P.-L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J., Seshan, V. E.
Publicado 2017